This meta-analysis underscores the potential benefits of SGLT2 inhibitors in reducing major adverse cardiovascular events, all-cause mortality, cardiovascular mortality, and hospitalization for cardiovascular reasons in patients with acute coronary syndrome (ACS). Here, SLC5A2 is linked to acute coronary syndrome.